About EpiBone
EpiBone is a Healthcare company based in Brooklyn (United States) founded in 2013 by Elisa Cimetta, Sarindr Bhumiratana, and Sidney Eisig. Developer of stem cells to regrow damaged bones. EpiBone has raised $48.63 million across 10 funding rounds from investors including HHS, Hackensack Meridian Health and EMV Capital. EpiBone offers products and services including Bioreactor and Personalized Bone Products. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its competitors include ViaCyte, Capricor Therapeutics and Neurona Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2013 and based in Brooklyn, United States, the company operates in the biotechnology sector focused on regenerative medicine. Custom autologous bone grafts are engineered through a bioreactor platform, where CT scan data is used to create anatomically shaped scaffolds. These scaffolds are seeded with stem cells from the patients own tissue and matured in a proprietary bioreactor system for bone preconditioning and development.
- Headquarters Brooklyn, United States
- Founders Elisa Cimetta, Sarindr Bhumiratana, Sidney Eisig
- SectorsHealthcare
- Email••••••••
- Website epibone.com
- Social LinkedIn X Instagram YouTube
- Total Equity Funding$48.63M (USD)
in 10 rounds
- Latest Funding Round$4.29M (USD), Series B
Sep 2025
- InvestorsHHS
& 7 more
Products & Services of EpiBone
EpiBone offers a comprehensive portfolio of products and services, including Bioreactor and Personalized Bone Products.
Device that grows personalized bone from stem cells for healing.
Custom-grown bone and cartilage to replace damaged tissue.
Funding Insights of EpiBone
EpiBone has successfully raised a total of $48.63M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $4.29 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $48.63M
- Total Rounds 10
- Last Round Series B — $4.29M
- Investors Count 8
All 10 funding rounds of EpiBone with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $4.29M | Series B | – | – | – |
| Nov 2024 | Series B | – | Kendall Capital Partners | ||
| Dec 2022 | $18.45M | Series B | – | – | – |
| Nov 2021 | $1M | Series B | – | – | |
| Feb 2021 | $750,000 | Debt – Conventional | – | – | – |
| Feb 2020 | $24.33M | Series B | – | – | |
| Oct 2016 | $560,000 | Seed | – | – | |
| Dec 2014 | Seed | – | – | ||
| Sep 2014 | $149,684 | Grant | – | – | |
| Jun 2014 | Grant | – | – |
8 investors in total: 8 institutional.
Investors in EpiBone
EpiBone has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Hackensack Meridian Health and EMV Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are focused on health technology breakthroughs. | kcpventures.com | Boston, United States | ||
| lifespanvisionventures.com | ||||
B2B-tech focused VC firm | 2018 | emvcapital.com | London, United Kingdom | |
Early-stage science-driven companies are supported through venture capital investments. | breakoutlabs.org | |||
Venture capital investments are made in deep tech and life sciences by EMV Capital. | 2013 | netscientific.net | London, United Kingdom | |
Standalone multispecialty hospitals are operated across the United States. | 2016 | hackensackmeridianhealth.org | Edison, United States | |
Funds are raised for women entrepreneurs via donation-based crowdfunding. | 2012 | plumalley.co | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for EpiBone
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EpiBone
20 people are tracked at EpiBone (6 in leadership, 6 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Elisa Cimetta | Co-Founder | Leadership |
Sarindr Bhumiratana | Co-Founder & CSO | Leadership |
Sidney Eisig | Co-Founder | Leadership |
Nina Tandon | CEO | Leadership |
Ph.D./Mba Nina Tandon | Ceo, Co-founder | Leadership |
Carla N. | Director Of Administration | Leadership |
Elma S. Hawkins | Board Chairman | Board & advisors |
Gordana Vunjak-Novakovic | Board Member, Scientific Advisor & Co-Founder | Board & advisors |
Cliff Schorer | Advisor | Board & advisors |
Brian Cole | Advisor | Board & advisors |
Hank Kucheman | Advisor | Board & advisors |
Beth Kauderer | Advisor & Board Observer | Board & advisors |
Rick Rivera | Business Manager | Team |
Carla Nassy | Office Manager | Team |
Angela Huang | Research Scientist & Injectables Lead | Team |
Huma Arastu | Senior Research Associate | Team |
Robert Morin | Physician Advisor/consultant | Team |
Ohad Oman | Consultant | Team |
Avraham Berkowitz | Senior Advisor | Team |
David Armstrong | Strategic Advisor | Team |
Complete people profiles for EpiBone
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EpiBone
3 dated milestones of EpiBone across 12 years, from founding to its latest funding, stage changes and deals.
- Founded EpiBone is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $4.3M.
Competitors of EpiBone
EpiBone has 3 listed competitors in our database, 2 of them funded. They include ViaCyte, Capricor Therapeutics and Neurona Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| capricor.com | 2005 | Los Angeles, United States | 62 | Regenerative medicine for cardiovascular disorders is developed using cell-based platforms. | ||
| neuronatherapeutics.com | 2008 | San Francisco, United States | $417.69M | 67 | Cell-based therapies are developed for intractable neurological diseases. |
Detailed competitors of EpiBone
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EpiBone
The website of EpiBone (epibone.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 7.8% vs previous month
Websites whose visitors overlap most with EpiBone. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gust.com | 100% | 210.3K | #203,214 | View details |
Top companies in Orthopedics
3 companies that operate in the same segment as EpiBone (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epibone
Complete news archive for EpiBone
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EpiBone
EpiBone was founded in 2013 and raised its 1st funding round 1 year after it was founded.
EpiBone is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.
EpiBone is a funded company, having raised a total of $48.63M across 10 funding rounds to date.
Founded in 2013 and based in Brooklyn, United States, the company operates in the biotechnology sector focused on regenerative medicine. Custom autologous bone grafts are engineered through a bioreactor platform, where CT scan data is used to create anatomically shaped scaffolds. These scaffolds are seeded with stem cells from the patients own tissue and matured in a proprietary bioreactor system for bone preconditioning and development.
EpiBone's top competitors include Neurona Therapeutics, Capricor Therapeutics and ViaCyte.
EpiBone offers Bioreactor and Personalized Bone Products.
EpiBone has 8 investors. Key investors include HHS, Hackensack Meridian Health, EMV Capital, Plum Alley Investments, and EMV Capital.